Showing results (71-80 of 127) with videos related to
Sort By:
Pageof 13
Annals of Clinical and Translational Neurology|May 20, 2026
Evaluation of Digital Technologies for Home-Based Assessment in People With Amyotrophic Lateral SclerosisArne Mueller, Vanessa Vallejo, Mónica Povedano Panadés, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 10, 2025
Quantifying multimodal longitudinal brain changes in presymptomatic C9orf72 diseaseDario Saracino, Lorenzo Cipriano, Marion Houot, et al.Neurobiology of Aging|October 18, 2015
TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohortsIsabelle Le Ber, Anne De Septenville, Stéphanie Millecamps, et al.International Journal of Molecular Sciences|August 14, 2025
Improving ALS Molecular Diagnosis Through Functional Assays: Reassessment of a <i>SOD1</i> Variant of Uncertain SignificanceLéa Bedja-Iacona, Arthur Forget, Chloé Boisseau, et al.Muscle & Nerve|December 12, 2022
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.Neurobiology of Aging|October 20, 2018
Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriersClémence Fournier, Mathieu Barbier, Agnès Camuzat, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 26, 2020
Plasma microRNA signature in presymptomatic and symptomatic subjects with <i>C9orf72</i>-associated frontotemporal dementia and amyotrophic lateral sclerosisVirgilio Kmetzsch, Vincent Anquetil, Dario Saracino, et al.Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 31, 2016
Semantic and nonfluent aphasic variants, secondarily associated with amyotrophic lateral sclerosis, are predominant frontotemporal lobar degeneration phenotypes in TBK1 carriersPaola Caroppo, Agnès Camuzat, Anne De Septenville, et al.Muscle & Nerve|June 9, 2025
Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of TreatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|August 12, 2010
The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trialsEttore Beghi, Adriano Chiò, Philippe Couratier, et al.Pageof 13